Single pivotal trials are becoming less the exception and more central to how drug development is structured. They're still applied case by case, but the direction is clear: clinical proof, regulatory review, and commercial preparation are increasingly happening at the same time.
That changes something fundamental. The first credible dataset is increasingly the launch dataset. Choices made inside that trial, on endpoints, comparators, patient population, now shape positioning, reimbursement, and adoption just as much as they shape approval.
A few things worth acting on: design your pivotal trial with payers and physicians in mind, not just regulators. Model access risk before trial design is locked. Move MSL and field strategy on early signals, not final data. And as the FDA explores AI-enabled continuous trials across all development phases, the organizations best placed to respond are those that have already connected their clinical and commercial systems.
Rohit Gupta lays out the full picture and a practical set of actions for commercial leaders navigating this shift.